Published Studies Related to Cathflo Activase (Alteplase)
Well-designed clinical trials related to Cathflo Activase (Alteplase)
Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial. [2008.11.12]
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. [2008.09.25]
Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial. [2007.06]
Short and long alteplase dwells in dysfunctional hemodialysis catheters. [2005.04]
Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. [2004.06.15]
Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: comparison with unfractionated heparin. [2003.10.15]
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. [2003.07]
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. [2003.05]
Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction. [2003.02]
Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. [2002.10.10]
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. [2002.04.15]
Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. [2002.04.15]
ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. [2002.02]
Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. [2002]
Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings. [2001.08]
Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. [2001.08]
Streptokinase versus alteplase and other treatments for acute and delayed thrombolysis of blood stains in clothing. [2000.12.23]
Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. [2000.12]
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. [2000.10.10]
Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction. [2000.08.01]
The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. [2000.04]
Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. [1999.12.01]
Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. [1999.11.02]
Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. [1999.10.01]
Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. [1999.07]
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. [1999.01]
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. [1998.12.22]
Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin. [1998.12.08]
Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. [1998.11.17]
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. [1998.10.17]
An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy. [1998.10]
Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group. [1998.09.15]
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. [1998.09]
Can we improve on front-loaded alteplase (r-TPA)? [1998.08]
Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. [1998.06]
Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. [1998.04]
Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. [1997.10.15]
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. [1997.08]
Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. [1997.07]
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. [1997.06]
Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. [1997.03.15]
[Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients] [1997]
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. [1996.09.01]
Left ventricular function after late thrombolysis with alteplase in myocardial infarction. [1996.05]
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. [1995.10.15]
Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction. [1995.10]
More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. [1995.06.01]
Two trials of reduced bolus alteplase in the treatment of pulmonary embolism. An overview. [1994.09]
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. [1994.09]
Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. [1994.05]
Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. [1994.03]
Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. The TEAM-3 investigators. [1994.01.01]
LATE assessment of thrombolytic efficacy with alteplase (rt-PA) six-24 hours after onset of acute myocardial infarction. [1993.12]
Double-blind randomized trial of alteplase versus placebo in patients with chest pain at rest. [1993.11]
Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours. [1993.01]
Early electrocardiographic changes in acute myocardial infarction treated by streptokinase or alteplase: a randomized study with dynamic, multi-lead, electrocardiographic monitoring. [1993]
Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). [1992.09]
Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators. [1992.07]
Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group. [1992.03]
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. [1992.02]
Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction. [1991.07.15]
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction. [1991.01]
Well-designed clinical trials possibly related to Cathflo Activase (Alteplase)
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke. [2009.10.15]
Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. [2009.10]
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke. Modified Randomized Exposure Controlled Trial (mRECT). [2009.09.10]
Efficacy and Safety of Low Dose rt-PA for the Treatment of Acute Pulmonary Thromboembolism: A Randomized, Multi-Center, Controlled Trial. [2009.09.09]
The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V. [2009.08]
Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET). [2009.08]
Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial. [2009.07.15]
Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. [2009.07]
Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. [2009.07]
Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke. [2009.07]
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. [2009.06.09]
Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. [2009.06]
High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. [2009.05.26]
The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients? [2009.05]
Effects of losartan on fibrinolytic parameters and von Willebrand factor in Chinese subjects with hypertension: a comparative study versus atenolol. [2009.05]
A method to determine stroke trial success using multidimensional pooled control functions. [2009.05]
Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. [2009.04]
High dose of red wine elicits enhanced inhibition of fibrinolysis. [2009.04]
Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. [2009.04]
Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. [2009.04]
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. [2009.04]
Preoperative predictors of postsurgical adhesion formation and the Prevention of Adhesions with Plasminogen Activator (PAPA-study): results of a clinical pilot study. [2009.04]
[Pharmacotherapy of stroke] [2009.03]
Desmoteplase in acute massive pulmonary thromboembolism. [2009.03]
Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke? [2009.03]
Oxfordshire community stroke project clinical stroke syndrome and appearances of tissue and vascular lesions on pretreatment ct in hyperacute ischemic stroke among the first 510 patients in the Third International Stroke Trial (IST-3). [2009.03]
Thrombolytic therapy for patients who wake-up with stroke. [2009.03]
Ultrasound enhancement of fibrinolysis. [2009.03]
Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke. [2009.03]
Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk. [2009.02.15]
Imaging-based thrombolysis trial in acute ischemic stroke-II (ITAIS-II). [2009.02]
Safety and dose-escalation study design of Transcranial Ultrasound in Clinical SONolysis for acute ischemic stroke: the TUCSON Trial. [2009.02]
Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial. [2009.02]
Value of the 12-lead electrocardiogram to define the level of obstruction in acute anterior wall myocardial infarction: correlation to coronary angiography and clinical outcome in the DANAMI-2 trial. [2009.01.24]
Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke? [2009.01.20]
Thrombolytic Therapy for Patients Who Wake-Up With Stroke. [2009.01.08]
Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure. [2009.01]
Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. [2009.01]
IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. [2009]
|
